培美曲塞、顺铂方案联合艾迪注射液治疗非小细胞肺癌的临床研究

Pemetrexe Cisplatin Aidi Injection in Treatment of Non-small Cell Lung Cancer

目的观察培美曲塞+顺铂联合艾迪注射液对非小细胞肺癌患者的疗效。方法观察组32例(肺鳞癌13例、肺腺癌19例,Ⅱ期7例,Ⅲa期8例,Ⅲb期11例,Ⅳ期6例),对照组32例(肺鳞癌12例、肺腺癌20例,Ⅱ期7例,Ⅲa期8例,Ⅲb期10例,Ⅳ期7例)治疗结束对两组患者的有效率、疾病控制率、白细胞下降及Karnof-sky评分进行评价。结果观察组总有效率为62.5%,疾病控制率为84.3%;对照组总有效率为34.4%,疾病控制率为59.4%;治疗前后的白细胞总数下降在Ⅲ°以上发生率,观察组为12.5%;对照组为28.3%;Karnof sky评分:观察组改善者18例,稳定者8例,对照组改善者12例,稳定者7例;两组间差异有统计学意义(P<0.05)。结论培美曲塞+顺铂方案联合艾迪注射液对非小细胞肺癌患者有较良好的疗效。

Objective To observe the effect of pemetrex＋cisplatin Aidi injection on non-small cell lung cancer effects.Methods Totally 32 patients（13 cases of squamous cell carcinoma,adenocarcinoma 19 cases,stage Ⅱ of 7 cases,Ⅲ a 8 cases,Ⅲ b of 11 cases,Ⅳ 6 cases）,control group 32 patients（12 cases of lung squamous cell carcinoma,20 cases of lung adeno cancer,Ⅱ of 7 cases,Ⅲ a 8 cases,Ⅲ b of 10 cases,Ⅳ of 7 cases）,at the end of treatment of the two groups,disease control rate,leukopenia and Karnof-sky score were evaluated.Results The total effective rate was 62.5%,disease control rate was 84.3%;control group,the total effective rate was 34.4%,Disease control rate was 59.4%;the total number of white blood cells before and after treatment decreased the incidence of Ⅲ ° above the observation group was 12.5%;control group was 28.3%;Karnof sky score： the observation group,18 cases improved,stable in 8 patients;in the control group,12 cases improved,stable in 7 patients;difference between the two groups was significant（P0.05）.Conclusion Pemetrexed＋cisplatin Aidi injection on non-small cell lung cancer patients had significantly better efficacy.